OncoMatch

OncoMatch/Clinical Trials/NCT05277688

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

Is NCT05277688 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies adjuvant concurrent chemoradiotherapy for cervical cancer.

Phase 3RecruitingRuijin HospitalNCT05277688Data as of May 2026

Treatment: adjuvant concurrent chemoradiotherapyTo evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage IA2, IB, IIA, IIB

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Must have received: radical hysterectomy — adjuvant

Accepted radical hysterectomy 3-4 weeks before

Cannot have received: chemotherapy

no previous chemotherapy

Cannot have received: radiotherapy

no previous...radiotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify